What is Leerink Partnrs’ Forecast for TNGX Q1 Earnings?

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Tango Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share. Leerink Partnrs also issued estimates for Tango Therapeutics’ Q2 2025 earnings at ($0.36) EPS and Q4 2025 earnings at ($0.31) EPS.

A number of other analysts also recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Tango Therapeutics in a research note on Thursday, December 5th. HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Tango Therapeutics in a research report on Friday, November 8th. Guggenheim lowered their price objective on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Finally, B. Riley reduced their target price on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, November 11th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $13.14.

Tango Therapeutics Trading Down 2.7 %

Shares of TNGX stock opened at $3.26 on Friday. The stock’s 50-day moving average price is $3.14 and its 200-day moving average price is $6.12. Tango Therapeutics has a 12-month low of $2.59 and a 12-month high of $12.89. The stock has a market capitalization of $350.19 million, a price-to-earnings ratio of -2.76 and a beta of 0.80.

Insiders Place Their Bets

In other news, CEO Barbara Weber sold 9,778 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $29,236.22. Following the completion of the sale, the chief executive officer now directly owns 1,631,264 shares of the company’s stock, valued at approximately $4,877,479.36. The trade was a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Mace Rothenberg purchased 10,000 shares of the business’s stock in a transaction dated Thursday, November 14th. The stock was bought at an average price of $3.62 per share, for a total transaction of $36,200.00. Following the completion of the acquisition, the director now owns 21,250 shares of the company’s stock, valued at approximately $76,925. The trade was a 88.89 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 24,268 shares of company stock valued at $72,561 over the last 90 days. Insiders own 6.30% of the company’s stock.

Institutional Trading of Tango Therapeutics

A number of large investors have recently modified their holdings of the company. Charles Schwab Investment Management Inc. raised its position in Tango Therapeutics by 5.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 513,429 shares of the company’s stock valued at $1,586,000 after purchasing an additional 26,192 shares in the last quarter. Los Angeles Capital Management LLC purchased a new position in shares of Tango Therapeutics during the fourth quarter valued at $218,000. Congress Asset Management Co. lifted its stake in Tango Therapeutics by 9.0% in the fourth quarter. Congress Asset Management Co. now owns 227,989 shares of the company’s stock worth $704,000 after acquiring an additional 18,919 shares during the period. Catalina Capital Group LLC bought a new position in Tango Therapeutics during the 4th quarter worth about $82,000. Finally, Barclays PLC increased its position in Tango Therapeutics by 78.3% during the 3rd quarter. Barclays PLC now owns 126,281 shares of the company’s stock valued at $972,000 after purchasing an additional 55,470 shares during the period. Hedge funds and other institutional investors own 78.99% of the company’s stock.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.